托法替布治疗风湿性多肌痛患者的疗效与安全性(EAST PMR):一项开放标签随机对照试验
研究纳入初治风湿性多肌痛患者,第一队列发现患者外周血单个核细胞炎症及细胞因子受体通路基因表达显著改变、可触发JAK信号,体外托法替布抑制CD4+T细胞IL-6R和JAK2表达;第二队列随机接受托法替布或糖皮质激素24周,主要及次要结局均无统计学显著差异,两组均无严重不良事件,局限为单中心、观察期短。
要点
- 初治风湿性多肌痛患者外周血单个核细胞JAK相关炎症基因表达显著升高。
- 随机对照中托法替布与糖皮质激素24周疗效无统计学显著差异。
- 两组均无严重不良事件,研究为单中心、观察期短。
核心结论
- JAK信号参与风湿性多肌痛发病机制。
- 在本随机、单中心、开放标签对照试验中,托法替布治疗风湿性多肌痛的疗效与糖皮质激素相当。
研究设计与样本
- 第一队列比较11例新诊断风湿性多肌痛患者(女10例、男1例,年龄68.0±8.3岁)与20例健康对照(女17例、男3例,年龄63.7±9.8岁)外周血单个核细胞RNA测序基因表达。
- 第二队列将风湿性多肌痛患者按1/1随机接受托法替布或糖皮质激素治疗24周。
- 39例新诊断风湿性多肌痛患者接受托法替布、37例接受糖皮质激素,分别有35例(女29例、男6例,年龄64.4±8.4岁)和32例(女23例、男9例,年龄65.3±8.7岁)完成24周干预。
- 于0、4、8、12、16、20、24周行临床和实验室检查并计算风湿性多肌痛活动度评分(PMR-AS)。
- 主要终点为第12周和第24周PMR-AS≤10的患者比例;次要终点为第12周和第24周PMR-AS评分、C反应蛋白(CRP)和红细胞沉降率(ESR)。
主要发现
- RNA测序显示患者与健康对照外周血单个核细胞基因表达模式显著不同,炎症反应和细胞因子-细胞因子受体相互作用为最显著受影响通路。
- 患者IL6R、IL1B、IL1R1、JAK2、TLR2、TLR4、TLR8、CCR1、CR1、S100A8、S100A12和IL17RA表达明显升高,可触发JAK信号。
- 体外托法替布抑制风湿性多肌痛患者CD4+T细胞的IL-6R和JAK2表达。
- 主要和次要结局均无统计学显著差异;第12周和第24周两组所有患者PMR-AS均<10。
- 两组PMR-AS、CRP和ESR均显著下降;两组均未观察到严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究局限包括单中心研究设计和观察期短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polymyalgia rheumatica (PMR) is a common inflammatory disease in elderly persons whose mechanism of pathogenesis has not been elucidated. Glucocorticoids are the main first-line treatments but result in numerous side effects. Therefore, there is a need to explore pathogenetic factors and identify possible glucocorticoid-sparing agents. We aimed to study the pathogenetic features of the disease and assess the efficacy and safety of Janus tyrosine kinase (JAK)-inhibitor tofacitinib in patients with PMR. METHODS AND FINDINGS: We recruited treatment-naïve PMR patients from the First Affiliated Hospital, Zhejiang University School of Medicine, between September 2020 and September 2022. In the first cohort, we found that the gene expression patterns of peripheral blood mononuclear cells (PBMCs) in 11 patients (10 female, 1 male, age 68.0 ± 8.3) with newly diagnosed PMR were significantly different from 20 healthy controls (17 female, 3 male, age 63.7 ± 9.8) by RNA sequencing. Inflammatory response and cytokine-cytokine receptor interaction were the most notable pathways affected. We observed marked increases in expression of IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, S100A8, S100A12, and IL17RA, which could trigger JAK signaling. Furthermore, tofacitinib suppressed the IL-6R and JAK2 expression of CD4+T cells from patients with PMR in vitro. In the second cohort, patients with PMR were randomized and treated with tofacitinib or glucocorticoids (1/1) for 24 weeks. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR activity disease scores (PMR-AS) were calculated. The primary endpoint was the proportion of patients with PMR-AS ≤10 at weeks 12 and 24. Secondary endpoints: PMR-AS score, c-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) at weeks 12 and 24. Thirty-nine patients with newly diagnosed PMR received tofacitinib, and 37 patients received glucocorticoid. Thirty-five patients (29 female, 6 male, age 64.4 ± 8.4) and 32 patients (23 female, 9 male, age 65.3 ± 8.7) patients completed the 24-week intervention, respectively. There were no statistically significant differences in primary or secondary outcomes. At weeks 12 and 24, all patients in both groups had PMR-AS <10. PMR-AS, CRP, and ESR were all significantly decreased in both groups. No severe adverse events were observed in either group. Study limitations included the single-center study design with a short observation period. CONCLUSIONS: We found that JAK signaling was involved in the pathogenesis of PMR. Tofacitinib effectively treated patients with PMR as glucocorticoid does in this randomized, monocenter, open-label, controlled trial (ChiCTR2000038253). TRIAL REGISTRATION: This investigator-initiated clinical trial (IIT) had been registered on the website (http://www.chictr.org.cn/, ChiCTR2000038253).
引用
- Ma X, Yang F, Wu J, et al. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023. PMID: 37384596. doi:10.1371/journal.pmed.1004249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。